Supernus Pharmaceuticals (SUPN) Change in Cash (2011 - 2026)

Supernus Pharmaceuticals has reported Change in Cash for 16 years, with the latest figure at -$4.9 million in Q2 2026.

• Change in Cash for Q2 2026 came in at -$4.9 million, down 117.03% year-over-year; the trailing twelve-month figure through Jun 2026 was $36.7 million (down 60.39% YoY), and the FY2025 annual result was $60.6 million, up 1158.31% from the prior year.
• Change in Cash eased to -$4.9 million in Q2 2026, from $56.4 million in the prior quarter.
• Over five years, Change in Cash peaked at $369.1 million in Q1 2023 and troughed at -$437.5 million in Q2 2023.
• A 5-year average of -$1.2 million and a median of -$8.1 million in 2024 frame the typical range for Change in Cash.
• The largest YoY upside for Change in Cash was 520.75% in 2023 against a maximum downside of 858.05% in 2023.
• A 5-year view of Change in Cash shows it stood at -$18.4 million in 2022, then declined by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then sank by 160.87% to -$22.9 million in 2025, then soared by 78.55% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$4.9 million in Q2 2026, $56.4 million in Q1 2026, and -$22.9 million in Q4 2025.